AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03364985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: DWP16001 placebo-matching tablets, Active control placebo-matching tablets
Study NCT00659633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Description: intravenous, effect site concentration: 2mcg/ml, 15-20 min infusion, once
Study NCT03364985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Forxiga®
Study NCT05990205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Life Style Intervention + Metformin
Description: hypocaloric diet, 25 kcal/kg of ideal weight, 45% of the total intake of carbohydrates, 30% lipids, and 25% protein sources + physical activity (>150 min medium intensity per week) + Metformin extended release 750mg each 12 hours
Study NCT05990205 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Life Style Intervention
Description: hypocaloric diet, 25 kcal/kg of ideal weight, 45% of the total intake of carbohydrates, 30% lipids, and 25% protein sources + physical activity (>150 min medium intensity per week)
Study NCT03884595 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: IG, IPF, NRBC, CRP, PCT, presepsin
Description: Assessment of blood cell count parameters and inflammation markers - IG, IPF, NRBC, CRP, PCT, presepsin according to study group.
Study NCT03218410 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical pulmonary embolectomy
Study NCT03218410 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: catheter-directed thrombolysis
Study NCT01866488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Study NCT01866488 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02175654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Study NCT00543582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGCD0103 and Azacitidine
Description: In Part 1 of the study, up to 22 people to enroll will receive a single, oral dose (75 mg gelcap) of MGCD0103 and FB-MGCD0103 during their first 2 weeks in the study. Up to 22 additional people will receive a single dose of both MGCD0103 and TA-FB-MGCE0103. The next group of people to enroll will receive 2 different single doses (25, 50, 100 mg) of FB-MGCD0103 or TA-FB-MGCD0103 during their first 2 weeks in the study.~In Part 2 of the study, from Day 1-5 of each 28-day cycle, all subjects will receive a dose of azacitidine (75 mg/m2) either subcutaneously or through an intravenous device, and on days 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, a single, oral dose (85 mg) of MGCD0103 until progression or unacceptable toxicity develops.
Study NCT02372682 — intervention group
Intervention type: DEVICE
Intervention: Shear wave sonoelastography
Description: Sonoelastography is to be performed on the liver.
Study NCT02482571 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mild Hypoxia
Description: During normoxia, the computer-controlled gas blender provides a gas mixture that generates pressures of expired O2 and CO2 similar to the resting values measured for each subject (32-35mmHg and 100-110 mmHg, respectively). During mild hypoxia, we will target the same expired CO2 of normoxia and a 60 mmHg reduction of expired O2 from the resting value (to a minimum limit of 50 mmHg), which is expected to reduce arterial oxygen saturation to 82-85%. In mild hypoxia, the fraction of inspired oxygen is reduced from \~21% (room air) to \~12% (equivalent to an altitude of 4000 meters). During both conditions of normoxia and mild hypoxia, the brain activity of subjects is monitored with functional magnetic resonance spectroscopy (fMRS) while they are presented with visual stimuli.
Study NCT01726335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone prolonged release
Description: Risperidone will be administered as intramuscular injection as 25 milligram (mg) every two weeks, from Week 1 to 50, wherein after Week 3, dose may be adjusted up to 50 mg at physician criterion. For first two weeks, previous oral antipsychotic drug will be maintained and the dose will be gradually decreased and will cease at Week 3.
Study NCT01420835 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Auriculotherapy (protocol group)
Description: The auriculotherapy points of the protocol group will be 5 points (Liver yang1, Liver yang2, Shenmen, Kidney, Brainstem), during 45 days, twice per week, 12 sessions and assessment of the follow-up (30 days) after finishing the treatment.
Study NCT01420835 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: without protocol group
Description: The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to balance the body energy and to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion. Five points will be chosen to treat stress according to the symptoms and the Chinese diagnosis.
Study NCT03861390 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Immediately following exit from the wood smoke chamber, subjects will receive a matching placebo to the 60 mg of prednisone per randomization schema
Study NCT00964574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLULISINE (HMR1964)
Description: Pharmaceutical form:~APIDRA 100U/ml flacon for the titration period in the hospital APIDRA 100U/ml solution for injection in cartridge in OptiSet~Route of administration:~3-4 subcutaneous injections per day
Study NCT00964574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLARGINE
Description: Pharmaceutical form:~LANTUS 100U/ml solution for injection in cartridge~Route of administration:~Once daily subcutaneous injection in the evening
Study NCT01667718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth
Description: Bismuth 220mg b.i.d for 2 weeks
Study NCT01667718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Lansoprazole 30 mg b.i.d.for 2 weeks
Study NCT01667718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Lansoprazole 30 mg b.i.d.for 2 weeks
Study NCT01667718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levoﬂoxacin
Description: Levoﬂoxacin 0.5 q.d. for 2 weeks
Study NCT01667718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levoﬂoxacin
Description: Levoﬂoxacin 0.5 q.d. for 2 weeks
Study NCT01667718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Amoxicillin 1 g b.i.d. for 2 weeks
Study NCT01667718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Amoxicillin 1 g b.i.d. for 2 weeks
Study NCT01325363 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetoencephalograph (MEG)
Description: Brain imaging device that records the magnetic fields in the brain.
Study NCT04161469 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laser closure of the anal fistula tract (FiLaC)
Description: The FiLaC procedure was performed using a ceramic diode laser platform (12 watts, 1470-nm wavelength). The laser fiber was introduced into the fistula tract via the external orifice using the seldinger maneuver until the internal orifice was found. The fiber delivered laser energy homogenously at 3600, causing shrinkage of the fistula tract around the fiber while it was withdrawn at the speed of 1 mm/s
Study NCT04161469 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Internal orifice closure
Description: Closure of internal orifice with a purse-string suture using 2-0 polyglactin suture material.
Study NCT01159041 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Focused Treatment (FFT)
Description: FFT is designed to specifically address the developmental needs of school-aged children and their parents through an emphasis on fostering positive and supportive parent-child interactions that scaffold the development of a positive self, to help parents provide the child additional positive feedback on his/her developmentally appropriate achievements, and to enhance family and child coping. This treatment is conducted with the child and his/her parent(s) and includes education about depression, communication training, relationship enhancement, and problem-solving.
Study NCT03358667 — intervention group
Intervention type: PROCEDURE
Intervention: augmentation peri-implant soft tissue
Description: the implant was cover with a 2 mm cover screw for a tent effect or with a dermal membrane after implant insertion
Study NCT01159041 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Treatment (IP)
Description: The goals of the treatment are to foster the therapeutic relationship, to provide a supportive and empathic setting where the child can come to better understand his/her emotions/feelings and address issues underlying current symptoms. Therapeutic goals will be addressed through reflection and clarification of feelings/emotions and understanding the child's perception of the context of depressed feelings.
Study NCT04410107 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lung Function tests
Description: Spirometry before and after bronchodilator, lung volumes by body plethysmography, lung diffusion capacity of carbon monoxide (DLCO), respiratory system resistance by impulse oscillometry (IOS)
Study NCT04410107 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Exercise capacity
Description: 6-minute walk test (6MWT distance)
Study NCT04410107 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Exercise physiology
Description: Cardiopulmonary exercise test (CPET)
Study NCT01638793 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microcap (Oridion, Needham, MA, USA)
Study NCT01638793 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smart Capno Line Plus O2 (Oridion, Needham, MA, USA)
Study NCT00492388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMI-150 (intranasal ketamine)
Description: intranasal dosing
Study NCT00492388 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT05037682 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dissemination and Implementation Research
Description: The study will employ a research and implementation design that attempts to balance scientific rigor, research good practices, primary care implementation preferences and numerous limitations related to the study context. A waitlist-controlled, staggered implementation study will be conducted with three groups of 15 practices introduced to the intervention in 3-month intervals, each baseline overlapping with interim measurements of care quality and process outcomes in concurrent groups in every 3 months, followed by a final data collection at the end of the intervention in months 16 and 17, including baseline measures plus semi-structured interviews. The groups and their sequence will not be randomized, but practice characteristics will be used to distribute them among the three groups based on location, type, size and patient mix to maximize the balance of practices among the groups.
Study NCT03213054 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OBP-301
Description: OBP-301 administration on the Day 1, Day 18 and Day 32
Study NCT03213054 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Standard radiation therapy for esophageal cancer patient. total 60 Gy for 6 weeks
Study NCT03899974 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test meal
Description: Participants received in random order the three test meal (700Kcal, 80g available carbohydrates) containing breads prepared with amylose-rich wheat flours (70% or 85%) or conventional flour. Blood samples were collected at fasting and every 30 minutes over 4 hours. Breath hydrogen was evaluated as a marker of intestinal fermentation. Participants underwent Visual Analogue Scale to assess subjective appetite sensations.~After 4 hours, all participants consumed a standard lunch (700 kcal, 100 g available carbohydrates) identical on all the three experimental days to evaluate the second meal effect from breakfast to lunch.
Study NCT03899974 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Test meal
Description: Participants received in random order the three test meal (700Kcal, 80g available carbohydrates) containing breads prepared with amylose-rich wheat flours (70% or 85%) or conventional flour. Blood samples were collected at fasting and every 30 minutes over 4 hours. Breath hydrogen was evaluated as a marker of intestinal fermentation. Participants underwent Visual Analogue Scale to assess subjective appetite sensations.~After 4 hours, all participants consumed a standard lunch (700 kcal, 100 g available carbohydrates) identical on all the three experimental days to evaluate the second meal effect from breakfast to lunch.
Study NCT01335399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug
Study NCT01335399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug
Study NCT01335399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Tablets, Oral, 40 mg, weekly, on Days 1, 8, 15, 22, Repeat every 28 days until subject meets criteria for discontinuation of study drug
Study NCT01335399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Tablets, Oral, 28 mg, once daily, on Days 1, 8, 15, 22 (cycles 1\&2) ; Days 1 \&15 (cycles 3-18); Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
Study NCT01335399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Tablets, Oral, 40 mg, once daily, on Days 8 \& 22 (cycles 3-18); Days 8, 15, 22 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
Study NCT01335399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Solution, Intravenous (IV), 8 mg, Once daily, on Days 1, 8, 15, 22 (cycles 1\&2) ; Days 1 \&15 (cycles 3-18); Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
Study NCT04410107 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Health-related quality of life
Description: Short-Form Health Survey Questionnaire (SF-36)
Study NCT04410107 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Respiratory symptoms, symptoms of anxiety and depression, and post-traumatic stress screening
Description: 1. Adapted translation American Thoracic Society respiratory symptoms questionnaire;~2. Beck Anxiety Inventory (BAI) and Beck's depression Inventory (BDI);~3. Questionnaire for screening for post-traumatic stress symptoms (PTSD).
Study NCT05796219 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Low dose mammogram
Description: Low dose mammogram
Study NCT03239535 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells
Description: Intramuscular injection
Study NCT03239535 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Intramuscular injection
Study NCT00722358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-650032
Description: Capsule, Oral, Q12h, 3/5 days~Panel 1: 200 mg~Panel 2: 400 mg~Panel 3: 600 mg
Study NCT00722358 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule, Oral, Q 12h, 3/5 days~Panel 1: matching placebo~Panel 2: matching placebo~Panel 3: matching placebo
Study NCT05798182 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound measurement
Description: Study was conducted with Mindray T7 ultrasound machine using linear probe. Vascular ultrasound mode was used with settings depth of 50 mm and gain of 40 dB during the entire study period. The diameter and flow velocity of the brachial artery and wrist edema of the fist were measured within 24 hours of admission and the following day.
Study NCT01335399 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Elotuzumab (BMS-901608; HuLuc63)
Description: Solution, Intravenous (IV), 10 mg/kg, weekly, on Days 1, 8, 15, 22 (cycles 1\&2); Days 1 and 15 (cycles 3-18), Repeat every 28 days until subject meets criteria for discontinuation of study drug
Study NCT01335399 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Elotuzumab (BMS-901608; HuLuc63)
Description: Solution, Intravenous (IV), 20 mg/kg, Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
Study NCT00524576 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix™-B
Description: One dose (10µg Hepatitis B surface antigen (HBsAg))
Study NCT00409188 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tecemotide (L-BLP25)
Description: After receiving cyclophosphamide, participants will receive 8 consecutive weekly subcutaneous vaccinations with 806 microgram (mcg) of tecemotide (L-BLP25) at Weeks 0, 1, 2, 3, 4, 5, 6, and 7 followed by maintenance vaccinations with 806 mcg of tecemotide (L-BLP25) at 6-week intervals, commencing at Week 13, until disease progression is documented.
Study NCT00409188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single low dose cyclophosphamide
Description: A single intravenous infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before first tecemotide (L-BLP25) vaccination.
Study NCT00409188 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single infusion (IV) of 0.9% Saline solution instead of cyclophosphamide but in the same calculated dose will be given three days before first placebo vaccination. Subjects will then receive eight consecutive weekly subcutaneous vaccinations with placebo at weeks 0; 1; 2; 3; 4; 5; 6 and 7 followed by maintenance placebo vaccinations at 6-week intervals, commencing at week 13, until disease progression is documented.
Study NCT02593188 — intervention group
Intervention type: BIOLOGICAL
Intervention: HYQVIA
Description: Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase
Study NCT02328261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: Icotinib (125 mg tablet) is orally administered three times daily until disease progression or unaccepted toxicity.
Study NCT02165566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular-insulin
Description: patients are assigned in a random sequence to receive Regular-insulin or lispro-insulin infusion
Study NCT02165566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lispro-insulin
Description: patients are assigned in a random sequence to receive Regular-insulin or lispro-insulin infusion
Study NCT03456362 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION
Description: theta burst stimulation (TBS) is a novel form of repetitive transcranial magnetic stimulation that mimics protocols inducing long-term potentiation (LTP) or long-term depression (LTD) in animal models. Whereas continuous TBS (cTBS) induces long-lasting inhibition of cortical areas, iTBS exerts the opposite effect, increasing cerebellar excitability
Study NCT03456362 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION
Description: theta burst stimulation (TBS) is a novel form of repetitive transcranial magnetic stimulation that mimics protocols inducing long-term potentiation (LTP) or long-term depression (LTD) in animal models. Whereas continuous TBS (cTBS) induces long-lasting inhibition of cortical areas, iTBS exerts the opposite effect, increasing cerebellar excitability
Study NCT02964897 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-support plus usual care from the Health Care for Reentry Veterans program
Description: a peer mentor who is also a veteran will establish a relationship with each subject and provide instrumental and emotional support to the subject during the first 6 months of the subject's release from incarceration. This is in addition to the usual reentry support provided by the Health Care for Reentry Veterans program.
Study NCT02964897 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual care from the Health Care for Reentry Veterans program
Description: Health Care for Reentry Veterans program provides reentry planning while the veteran is incarcerated. An outreach worker visits the veteran in the incarceration facility to conduct a needs assessment and help create a reentry plan to cover issues such as where they will be housed, what health care appointments they will need in the first 30 days, whether they need legal assistance, etc.
Study NCT01260480 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [18F]-ML-10 in conjunction with PET imaging
Description: Subjects will receive two to three intravenous (IV) doses of \[18F\]-ML-10. The dose for each \[18F\]-ML-10 dose will be 5.50 MBq/Kg or 0.15 mCi/Kg but will not exceed 500.00 MBq (13.50 mCi) per administration.
Study NCT03604354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol 100 MG Oral Tablet
Description: This arm will receive drugs one hour before undergoing unilateral total knee arthroplasty. Interventions tapentadol 100mg oral tablets.
Study NCT03604354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 150mg
Description: This arm will receive drugs one hour before undergoing unilateral total knee arthroplasty. Interventions pregabalin 150mg oral tablets.
Study NCT01411670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human protein C concentrate
Description: Continuous infusion of human protein C concentrate at the dose of 3 UI/Kg/Hr to reach a protein C plasma activity of 70-120%